This trial is evaluating whether COVID-19 Vaccine will improve 5 primary outcomes in patients with Respiratory Tract Infections. Measurement will happen over the course of 1 year.
This trial requires 30 total participants across 1 different treatment group
This trial involves a single treatment. COVID-19 Vaccine is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
"The present study supports the occurrence of a major component of heritability for the familial aggregation of respiratory infections, although the magnitude of such a familial component remains unclear." - Anonymous Online Contributor
"A total of 25% of HMPE patients had at least one respiratory tract infection. We speculate that the number may be higher with a higher HMPE severity." - Anonymous Online Contributor
"Atypical pneumonia, or community-acquired pneumonia, is an important cause of acute respiratory illness in the community and a common reason for hospital admission. The vast majority of ambulatory cases of pneumonia are not caused by atypical pathogens. However, the majority of cases are prevented by appropriate antibiotic therapy." - Anonymous Online Contributor
"Results from a recent paper does not support the hypothesis that patients with MDR-TB can be cured to a degree comparable to non-resistant, smear-negative patients. Patients with advanced TB should be provided prompt treatment for active symptoms, which can help to prevent further transmission." - Anonymous Online Contributor
"Respiratory infections are common in children and may be associated with a number of signs and symptoms. The most common are cough (97%) and upper airways obstruction. Children with unexplained fevers and lower respiratory tract signs and symptoms merit special consideration." - Anonymous Online Contributor
"Approximately 16 million people get respiratory tract infections a year in the United States. People over age 5 and people with underlying diseases tend to have increased rates of infections. Approximately 5 to 10% of respiratory tract infections are caused by strains of bacteria for which selective antibiotic treatment is available. The potential for antibiotic resistance is present if antibiotics are prescribed indiscriminately. There is a high rate of utilization of antibiotics by ambulatory settings, including physicians' office visits, in the United States when they are not medically indicated." - Anonymous Online Contributor
"RTI cause more or less 25% of hospitalizations in children under the age of 5 years. The main diagnostic factors are the need for mechanical ventilation, respiratory rate above 40+/min and white cell count over 10×10. The treatment consists primarily and not necessarily on antibiotics; prophylaxis of RTIs are not used mainly." - Anonymous Online Contributor
"Respiratory infections are common in healthcare centres, and most individuals receive some type of treatment for them. When antibiotics are prescribed, they usually are to treat presumed bacterial infections. Most treatments for a respiratory infection also have other systemic effects (e.g., sedation or nausea). Respiratory tract infections are commonly treated with antibiotics of the beta-lactam or macrolide class. The treatments for a viral infection tend to be less active, although steroids or antivirals (e.g., zanamivir) can be of utility if this is the problem." - Anonymous Online Contributor
"The SARS vaccination trial demonstrated that the vaccine is safe and immunogenic in adults and will protect against infection with SARS coronavirus. SARS-CoV-2 is a similar viral pathogen that can cause disease similar to SARS. The SARS-CoV-2 virus is highly infectious; the virus is transmitted from person to person. As a result, people should consider staying at home, staying vigilant and wearing face masks if there is an outbreak in their community, as is currently recommended by the US CDC." - Anonymous Online Contributor
"The data we reviewed are limited but may shed some light on potential immunogenicity of vaccine formulations against COVID-19, and the relevance of antigenically diverse viruses. There is an urgent need to fund prospective, randomized control studies to determine whether a standardized dose vaccine against COVID-19 will confer protection to recipients against disease in a susceptible population." - Anonymous Online Contributor
"The CV-19 vaccine in the current Phase 1b trials appears to be well tolerated by all participants and produces high rates of protection against CV-19 infection. The CV-19 vaccine shows a promising safety profile in CV-19 disease and therefore is a promising vaccine candidate for further evaluation. Clinical Trials Registry Number: NCT02277789." - Anonymous Online Contributor
"Patients with SARS or MERS virus infection were typically prescribed an antiviral treatment in addition to vaccination during their initial medical management. However, no studies were found that demonstrated the use of a vaccine in addition to another treatment for an SARS or MERS infection. However, further study on vaccine use for treatment in addition to other therapies may be beneficial." - Anonymous Online Contributor